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lished treatment guidelines. METHODS: Medicaid recip-
ients at least 16 years of age with at least one primary
diagnosis of schizophrenia (ICD-9-CM = 295) between
1998–2000 were identiﬁed from the Georgia and Cali-
fornia (20% random sample) Medicaid claims databases.
Polypharmacy cohorts were built in a hierarchical fashion
based on the antipsychotic use proﬁle of the schizophre-
nia patients and in accordance with published treatment
guidelines i.e. any polypharmacy, clozapine (clozapine +
atypical; clozapine + conventional), non-clozapine (atyp-
ical + atypical; conventional + conventional; and atypical
+ conventional) and long-term i.e. duration of use >2
months. Total 3-year prevalence of polypharmacy,
mean/median duration of episodes and year wise trends
in usage were estimated. All results were reported by state
and in aggregate. RESULTS: Out of a total of 31,435
persons with schizophrenia, the overall prevalence of
antipsychotic polypharmacy was 40% (n = 12,549, mean
age: 43 years, Caucasian: 47%, female: 48%) over
1998–2000 and was 46% in California compared to 35%
Georgia (p < 0.0001). Long-term polypharmacy (expo-
sure > 2 months) had a prevalence rate of 23% (n = 7222)
with a long-term episode lasting a median of 197 days.
Among the long-term groups, non-clozapine polyphar-
macy was around 8 times more prevalent than clozapine
polypharmacy (p < 0.0001) and long term non-clozapine
atypical + conventional had the highest prevalence of
16%. Except for clozapine + conventional (no change)
and conventional + conventional (decreased) polyphar-
macy, all polypharmacy prevalences increased from 1998
through 2000 (Cochran-Armitage test; p < 0.0001).
CONCLUSIONS: The overall polypharmacy prevalence
rate of 40% is similar to that observed in other studies.
Average long-term polypharmacy with a median duration
of over 6 months and signiﬁcantly higher prevalence of
non-clozapine vs. clozapine polypharmacy contradicts
treatment guidelines and may be a cause for concern.
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OBJECTIVES: The purpose of this study was to investi-
gate use sedative/hypnotic drugs in a generally ambula-
tory population of persons 65+ years of age. Clinical
literature suggests that use of these agents is accompanied
by physical and mental functioning declines that pose par-
ticular concerns for non-institutionalized older individu-
als. METHODS: Retrospective analysis of sedative/
hypnotic claims from a database. Persons with at least
one prescription for a sedative/hypnotic in a 12-month
study period (January 1, 2001–December 31, 2001), who
were 65 years of age or older and were continuously
enrolled in the 6 months prior to the end of the study
period were included. Sedative/hypnotic agents included
barbiturate and non-barbiturate sedative hypnotics alone
or in combinations. Claims histories were used to identi-
ﬁed naïve users; current use was categorized as acute,
limited, or continuous based on days supply and reﬁll pat-
terns. RESULTS: Eight and a half percent of the 313,038
persons meeting inclusion criteria had at least one claim
for sedative/hypnotic agents. Of these 38% (n = 10,010)
were classiﬁed as naïve users. For these patients the mean
number of days of therapy for the initial prescription was
28.0 ± 15.1. Only 9% of naïve users received an initial
prescription for less than a 10 day supply; 8% received
initial prescriptions for >31 days; some up to a 90-day
supply. Short-term use was identiﬁed in less than 1/3 of
naïve users; 15% continued sedative/hypnotic use for
greater than 3 months. Twenty-eight percent of naïve
users received prescriptions for agents identiﬁed as poten-
tially inappropriate in elderly patients (21% received a
“never-use” drug). CONCLUSIONS: Sedative/hypnotic
utilization patterns in elderly ambulatory patients, par-
ticularly the evidence of non-adherence to clinical pre-
scribing recommendations related to initial drug selection
and days of therapy, should be of concern.
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OBJECTIVES: To examine treatment and pharmaceuti-
cal utilization patterns for patients receiving risperidone,
olanzapine or quetiapine in a VA system. METHODS:
This study used electronic claims data (VISTA system) 
to identify subjects prescribed atypical antipsychotics
between January 1, 1996 and June 30, 2001. Included
subjects were prescribed at least one study medication
and had at least two markers for any of the following
mental health disorders: bipolar, depression, schizophre-
nia, schizoaffective disorder, dementia, or PTSD. Demo-
graphics, average dose by diagnosis, adherence to VA
Guidelines, duration of therapy, concomitant medica-
tion use, and switching were analyzed descriptively.
RESULTS: Of 7658 total study patients, the following
number of patients received at least 1 prescription for the
following drugs: olanzapine (4363), risperidone (3878),
quetiapine (1387). The proportion of subjects with a
schizophrenia diagnosis receiving dose ranges consistent
with VA published guidelines for olanzapine, risperidone,
and quetiapine were 90, 75 and 41% respectively, but
varied greatly by diagnosis. Mean duration of therapy for
